Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia

Sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
Study ID
NCT04873141
Status
Completed

Conditions

  • Covid-19 Pneumonia
  • Cytokine Release Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Tocilizumab (TCZ), interleukin-6 (IL-6), newly appeared as treatment of cytokine release syndrome (CRS) in patients with severe covid-19 associated pneumonia. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients.

Key Dates

Start date
Apr 28, 2020
Status verified
May 2021
Primary completion
Jun 22, 2020
Completion
Jun 22, 2020

Study Design

Enrollment
24 participants (actual)

Arms

  • Arm: Case Group
    All the patients suffering from severe covid pneumonia and laboratory parameter suggestive of cytokine release syndrome.

Primary Outcome Measure

Mortality Rate [ Time Frame: 28 days ]

Related Studies